Document is current
Any future updates will be listed below
-
Authors
Zanoni, Michele https://orcid.org/0000-0003-1826-9430
Sarti, Alba Clara
Zamagni, Alice
Cortesi, Michela
Pignatta, Sara https://orcid.org/0000-0001-5464-0052
Arienti, Chiara https://orcid.org/0000-0002-2265-828X
Tebaldi, Michela
Sarnelli, Anna https://orcid.org/0000-0001-5986-3845
Romeo, Antonino
Bartolini, Daniela
Tosatto, Luigino
Adinolfi, Elena https://orcid.org/0000-0001-8129-9929
Tesei, Anna https://orcid.org/0000-0002-8351-5952
Di Virgilio, Francesco https://orcid.org/0000-0003-3566-1362
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG16812)
Associazione Italiana per la Ricerca sul Cancro (IG22837)
Associazione Italiana per la Ricerca sul Cancro (IG 13025)
Associazione Italiana per la Ricerca sul Cancro (IG 18581)
Associazione Italiana per la Ricerca sul Cancro (IG 22883)
Ministero della Salute (RF-2011-02348435)
- License Information
-
More Information
Article History
Received: 25 August 2021
Revised: 17 December 2021
Accepted: 11 January 2022
First Online: 24 January 2022
Competing interests
: Francesco Di Virgilio is a member of the Scientific Advisory Board of Biosceptre Ltd, a UK-based company involved in the development of P2X7-targeted antibodies. The remaining authors declare no competing interests.
